<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336842">
  <stage>Registered</stage>
  <submitdate>21/04/2011</submitdate>
  <approvaldate>27/04/2011</approvaldate>
  <actrnumber>ACTRN12611000432910</actrnumber>
  <trial_identification>
    <studytitle>The effect of Amlamax (made from Indian gooseberry) on raising good cholesterol.</studytitle>
    <scientifictitle>A Pilot Clinical Study to Evaluate the Potential of AMLAMAX (trademark (TM)) (Emblica Officinalis) Extract on Raising HDL-Cholesterol levels and Decreasing Plasma Amyloid beta Levels in  subjective memory complainers with low HDL-C.</scientifictitle>
    <utrn>U1111-1120-9548</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>'Subjective Memory function'</healthcondition>
    <healthcondition>Cardiovascular risk factors with metabolic syndrome such as hypertension, Obesity, dyslipidemia</healthcondition>
    <healthcondition>Alzheimer's Disease.</healthcondition>
    <healthcondition>Low high density lipoprotein cholesterol (HDL-C).</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Epidemiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Nutritional therapy using a standardised amla extract from Indian gooseberry in raising HDL-C i.e. good cholesterol and decreasing beta amyloid, the main protein involved in the pathogenesis of Alzheimer's Disease.

Duration: A randomized double-blind-placebo-control study for a period of 6 months.

Mode of administration: oral administration.

Dose: Ingestion of 2 x 500 mg AmlamaxTM  capsules /Placebo (1g/day total).</interventions>
    <comparator>A randomized double-blind-placebo-control study will be performed for a period of 6 months. Eligible subjects will be divided in two groups, an experimental group consuming the supplement AmlamaxTM and a control group consuming a placebo capsules. the main component for the placebo capsules is starch.

Group I  Ingestion of 2 x 500 mg AmlamaxTM  capsules (1g/day total), one in the morning and one at bed time  with a glass of water.
Group II - Ingestion of 2 x 500 mg placebo  capsules (1g/day total)  one in the morning and one at bed timewith a glass of water. 
The placebo  capsules will be identical in size and look to the AmlamaxTM capsules.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Raise high density lipoprotein  cholesterol. 

Lipid Analysis
Blood samples will be sent to a certified medical laboratory (PathWest, Perth, Western Australia) for determination of lipid concentrations (i.e. Total Cholesterol, LDL-C, HDL-C and Triglycerides).</outcome>
      <timepoint>baseline (0) months, 2 months, 4 months and 6 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Decrease in beta amyloid levels.

A sensitive double-antibody sandwich ELISA assay will be used for the detection and measurement of amyloid beta 40 and Amyloid beta 42 levels in the plasma.</outcome>
      <timepoint>baseline (0) month, 2 months, 4 months and 6 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>NIL</outcome>
      <timepoint>NIL</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria: The eligibility criteria will be as follows: 1) age 35-65 years, 2) HDL-C levels &lt;1.03 mMol/L in men or &lt;1.29 mMol/L in women 3) triglyceride  (TG) levels &gt;1.7 mMol/L.

psychometric testing using standardized, validated diagnostic tools.
 Mini-Mental State Examination (MMSE) score greater than or equal to 24.
2. The classification of SMC will be  obtained from a single question, yes/no response from the CAMDEX-R (Do you have any difficulty with your memory?
2.A score greater than or equal to 80-81 (CAMCOG)-R (cognitive component of the CAMDEX-R).
4. a score of below, equal and above age and education norms on the California Verbal Learning Test (CVLT).</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients suffering from heart failure, chronic liver disease, eGFR&lt;60 ml/min.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A randomized double-blind-placebo-control study will be performed for a period of 6 months. Eligible subjects will be divided in two groups, an experimental group consuming the supplement AmlamaxTM and a control group consuming a placebo .

Allocation will invove by contacting the holder of allocation schedule who is at central administration.</concealment>
    <sequence>Simple randomisation using randomisation table from a statistic book.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/05/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>167</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof Ralph Martins</primarysponsorname>
    <primarysponsoraddress>Center of Excellence in Alzheimer's Disease Research and Care
School of Excercise, Biomedical and Health Science
Edith Cowan University
270 Joondalup Drive
Joondalup
WA 6027</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Hollywood Private Hospital</fundingname>
      <fundingaddress>Monash Avenue
Nedlands
WA, 6009.</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Edith Cowan University</fundingname>
      <fundingaddress>270 Joondalup Drive
Joondalup
WA 6027</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Arjuna Natural Extracts LTD, Kerala, India.</sponsorname>
      <sponsoraddress>PB 126 Bank Road
Alwaye
Kerala, India
683 101</sponsoraddress>
      <sponsorcountry>India</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Several evidence support the notion that increase in total plasma cholesterol, low-density lipoprotein-cholesterol (LDLC), and decreased high-density lipoprotein-cholesterol (HDL-C) are risk factors for cardiovascular disease (CVD). Epidemiological studies have reported that high concentrations of HDL-C or "good" cholesterol (&gt;1.5mMol/L) may also be protective against Alzheimers disease (AD).

 AmlamaxTM developed by the R&amp;D lab of Arjuna Natural Extracts Limited (Kerala, India) is a dry extract from fresh fruits of Amla, which has shown remarkable results in increasing HDL-C levels. Therefore, the objectives of this proposed study will be to explore the effectiveness of the herbal extract AmlamaxTM on raising HDL cholesterol levels in population of subjects with low HDL-C levels drawn from the Perth memory cohort study, as well as to determine whether directly raising HDL-C levels can result in a decrease in plasma beta amyloid levels.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hollywood Private Hospital Ethics Committee</ethicname>
      <ethicaddress>Monash Avenue
Nedlands
WA 6009</ethicaddress>
      <ethicapprovaldate />
      <hrec>HPH 300</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Edith Cowan University</ethicname>
      <ethicaddress>270 Joondalup Drive
Joondalup
WA 6027</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Ralph Martins</name>
      <address>Centre of Excellence for Alzheimer's disease research and Care
School of Exercise, Biomedical and Health Sciences
Edith Cowan University, Joondalup
270 Joondalup Drive, Joondalup, WA, 6027</address>
      <phone>+61 8 6304 5456</phone>
      <fax>+61 8 6304 5851</fax>
      <email>r.martins@ecu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof Ralph Martins</name>
      <address>Centre of Excellence for Alzheimer's disease research and Care
School of Exercise, Biomedical and Health Sciences
Edith Cowan University, Joondalup
270 Joondalup Drive, Joondalup, WA, 6027</address>
      <phone>+61 8 6304 5456</phone>
      <fax>+61 8 6304 5851</fax>
      <email>r.martins@ecu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sajla Singh</name>
      <address>Centre of Excellence for Alzheimer's disease research and Care
School of Exercise, Biomedical and Health Sciences
Edith Cowan University, Joondalup
270 Joondalup Drive, Joondalup, WA, 6027</address>
      <phone>+61 8 6304 5852</phone>
      <fax>+61 8 6304 5851</fax>
      <email>s.singh@ecu.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>